Arcus Biosciences, Inc. (NYSE:RCUS) Receives $30.25 Consensus Price Target from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has been given an average rating of “Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $30.25.

RCUS has been the topic of several research analyst reports. HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Bank of America dropped their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Finally, Morgan Stanley reduced their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $10.06 per share, with a total value of $201,200.00. Following the purchase, the director now owns 28,400 shares in the company, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Terry J. Rosen acquired 19,800 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, with a total value of $201,564.00. Following the acquisition, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. The trade was a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. R Squared Ltd acquired a new position in Arcus Biosciences in the 4th quarter valued at about $26,000. Point72 Hong Kong Ltd acquired a new position in Arcus Biosciences in the third quarter valued at approximately $47,000. Lazard Asset Management LLC grew its position in Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after acquiring an additional 6,078 shares during the period. US Bancorp DE increased its stake in Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after acquiring an additional 6,615 shares during the last quarter. Finally, Quest Partners LLC raised its position in Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $9.15 on Friday. Arcus Biosciences has a one year low of $8.95 and a one year high of $19.11. The company has a market capitalization of $962.43 million, a PE ratio of -2.91 and a beta of 1.36. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The company has a 50-day simple moving average of $12.13 and a two-hundred day simple moving average of $14.82.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. The business had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Research analysts expect that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.